©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Human Native Soluble CD40L Is a Biologically Active Trimer, Processed Inside Microsomes (*)

(Received for publication, October 16, 1995; and in revised form, January 16, 1996)

Fabienne Pietravalle Sybille Lecoanet-Henchoz Horst Blasey Jean-Pierre Aubry Greg Elson Michael D. Edgerton Jean-Yves Bonnefoy (§) Jean-François Gauchat

From the Glaxo Institute for Molecular Biology, 14 Chemin des Aulx, 1228 Plan les Ouates, Geneva, Switzerland

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

CD40 ligand (CD40L) is a glycoprotein expressed on the surface of activated helper T cells, basophils, mast cells, and eosinophils. Binding of CD40L to its receptor CD40 on the B cell surface induces B cell proliferation, adhesion, and immunoglobulin class switching. We have identified soluble cleavage products of human CD40L in the supernatant of a stimulated human T cell clone. Subcellular fractionation experiments have shown that the transmembrane CD40L is processed inside the microsomes and that its cleavage is stimulation-dependent. The native human soluble CD40L is trimeric and, when used in conjunction with interleukin-4, induces B cell proliferation.


INTRODUCTION

CD40L is a type II surface protein expressed by T cells, basophils, mast cells, and eosinophils(1, 2, 3, 4, 5) . CD40L can induce B cell proliferation and is involved in the control of immunoglobulin (Ig) class switching(1, 2, 3, 6, 7) . Patients expressing mutated forms of CD40L (hyper-IgM syndrome) have lymph nodes without germinal centers and fail to produce the Ig isotypes requiring a class switch(8, 9, 10, 11, 12) . CD40L belongs to a family of surface proteins that exist in soluble and membrane-bound forms such as TNF-alpha (^1)and Fas ligand(13, 14) . We previously observed that recombinant, truncated forms of CD40L could be trimeric and biologically active(15) . We therefore examined if activated T cells could release soluble forms of CD40L. We detected soluble forms of CD40L similar to the ones recently described by Graf et al.(16) . These forms behaved as trimers and resulted, at least partially, from an intracellular processing. Soluble CD40L was active in B cell proliferation assays in the presence of IL-4. This suggests that both the soluble and membrane-bound forms of CD40L share biological activities and that cleavage of the membrane form might not simply represent an alternative way to down-regulate CD40L expression.


MATERIALS AND METHODS

Induction of CD40L Expression

The human T cell clone JF7 was maintained in Iscove's medium supplemented with transferrin (20 µg/ml), insulin (5 µg/ml), rIL-2 (100 units/ml), and fetal calf serum. Every 3 weeks, cells were diluted to a density of 2 times 10^5 cells/ml and stimulated with phytohemagglutinin (0.2 µg/ml, Wellcome) and irradiated peripheral blood mononuclear cells (5 times 10^5 cells/ml). For induction of soluble CD40L production, 2 times 10^9 cells at a density of 1 times 10^7/ml were stimulated for 16 h with ionomycin (1 µM) and phorbol myristic acetate (10 ng/ml) in Iscove's medium supplemented with transferrin, insulin, and rIL-2.

Detection of CD40L Surface Expression

Aliquots of cells (4 times 10^5 in 40 µl) were either incubated with soluble CD40-Fc (1 µg/ml), anti-CD40L mAb (1 µg/ml, kindly provided by R. Noelle, Darmouth Medical School, Lebanon, NH), or isotype-matched controls, followed by fluorescein isothiocyanate-labeled sheep anti-mouse IgG (France Biochem, Meudon, France) and propidium iodide (2 µg/ml) and analyzed by flow cytometry.

Preparation of CD40L-containing Supernatants

Cell supernatants were cleared from cellular debris by two centrifugations at 5000 times g for 20 min, filtered through a 0.2-µm cellulose acetate membrane, and concentrated times 200 using Amicon membranes with a 5-kDa cutoff.

Sedimentation of Soluble CD40L on a Sucrose Gradient

0.1 ml of concentrated supernatants of unstimulated or stimulated JF7 cells were mixed with 10 µl of biotinylated protein molecular weight marker (Amersham Corp.) and loaded on a 12-ml 5-20% w/v linear sucrose gradient. The gradient was centrifuged at 4 °C for 42 h in a SW 41 Ti rotor. Fractions (36) were collected, and the proteins contained in each fraction were analyzed by Western blot. Briefly, half of each fraction was taken and the proteins contained within were precipitated with 20% trichloroacetic acid. The remaining half of each fraction was cleared from sucrose by dialysis through a 5-kDa membrane cutoff and further tested for its ability to induce B cell proliferation.

Subcellular Fractionation of T Cells

For detection of CD40L in unfractionated cells, 2 times 10^7 unstimulated or stimulated cells were lysed in 100 µl of SDS gel loading buffer. For subcellular fractionation, around 3 times 10^9 cells, resuspended in 5 ml of PBS, were passed 20 times through a ball homogenizer(17) . Nuclei and intact cells were separated from the other cell fractions by centrifugation at 1000 times g. Microsomes were isolated by centrifugation at 100,000 times g for 60 min and lysed on ice for 30 min in radioimmune precipitation buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium lauryl sulfate, 50 mM Tris-HCl, pH 8.0, 1 mM phenylmethylsulfonyl fluoride, 10 mM benzamidine hydrochloride, 50 mM aminocaproic acid, and 20 mM iodoacetamide). Microsome-associated protein fractions were diluted with 1 volume of 2 times SDS gel loading buffer.

SDS-Polyacrylamide Gel Electrophoresis and Western Blotting

Protein samples were analyzed by SDS-PAGE on 14% acrylamide gels (Novex) and elecrotransferred to nitrocellulose membranes(18) . Nitrocellulose membranes were blocked in PBS containing 5% nonfat dry milk and 0.15% Tween 20 for 1 h at room temperature and incubated overnight at 4 °C with anti-CD40L mAb (5 µg/ml) diluted in the same buffer. Detection of the bound anti-CD40L mAb was performed using horseradish peroxidase-labeled sheep anti-mouse antibody and enhanced chemiluminescence (Amersham Corp.) according to the instructions of the manufacturer.

B Cell Proliferation Assay

Triplicate cultures of 2 times 10^5 tonsillar B cells in RPMI 1640 medium supplemented with 10% fetal calf serum were incubated either alone, with rIL-4 (200 units/ml), with rIL-4 and anti-CD40 mAb (1 µg/ml, B20, Serotec, Oxford, UK), or with IL-4 and the indicated amounts of the sucrose gradient fractions 3 and 19. When added, CD40-Fc was used at 10 µg/ml. After 72 h, [^3H]deoxythymidine (0.25 µCi/culture) was added for 6 h and incorporation was measured.


RESULTS AND DISCUSSION

Identification of Human Soluble CD40L in Activated T Cell Clone (JF7) Supernatant

In an attempt to detect soluble forms of the human CD40L released by activated CD4 T cells, we stimulated the T cell clone JF7 (19) with PMA and ionomycin for 16 h. This led to expression of surface CD40L, easily detectable by flow cytometry with anti-CD40L mAb (Fig. 1) or soluble CD40-Fc (data not shown). To identify soluble forms of the CD40L released into the cell culture medium, supernatant from unstimulated T cells or supernatant from T cells stimulated with PMA and ionomycin was cleared from cell debris, concentrated by ultrafiltration, and analyzed for the presence of CD40L by Western blotting assays using anti-CD40L mAb. Three soluble forms of CD40L were observed (Fig. 2). Two forms migrated as a doublet with an apparent molecular mass of 18 kDa (Fig. 2). The third form migrated with an apparent molecular mass of 15 kDa when subjected to SDS-PAGE (Fig. 2). The nature of the protein detected by Western blotting was checked by sequencing of the NH(2) ends. The Edman degradation was successful only for the 18-kDa band. The sequence obtained (MQKGD) indicated that the 18-kDa forms corresponded to the form described by Graf et al.(16) .


Figure 1: CD40L surface expression. 2 times 10^9 JF7 cells were unstimulated (A) or stimulated (B) for 16 h using ionomycin and PMA. Cells were incubated with the human anti-CD40L mAb or with IgG2a, then stained with fluorescein isothiocyanate-conjugated anti-mouse antibodies, and analyzed by flow cytometry.




Figure 2: The native human soluble CD40L is processed inside the microsomes. After 16 h with (lane 2) or without (lane 1) PMA and ionomycin, supernatants of JF7 cells were 200 times concentrated. In parallel, 2 times 10^9 cells were used to prepare microsomes from control (lane 3) and activated (lane 4) JF7 cells, and 2 times 10^7 cells were used to prepare total cell extract from the control (lane 6) and activated (lane 7) JF7 cells. Proteins from each fraction were titrated, and 30 µg/ml was subjected to SDS-PAGE analysis, transferred on nitrocellulose, and blotted with 5 µg/ml the human anti-CD40L mAb. The molecular mass marker is shown on lane 5.



To determine whether the soluble forms corresponded to a cleavage of the membrane form on the T cell surface or to an intracellular processing, we isolated microsomal fractions from unstimulated and stimulated JF7 cells and analyzed the fractions by Western blot assays with anti-CD40L mAb (Fig. 2). Whereas in the total cell extract and the microsomal fractions of the unstimulated T cell clone only the 33-kDa membrane form of CD40L could be detected, in activated cells the membrane-bound form and the 18- and 15-kDa forms were detectable (Fig. 2). These data suggest that the soluble forms released into the supernatant are the result of an intracellular cleavage event dependent on an enzymatic activity only present in stimulated cells. Based on the known IL-1beta and the TNF-alpha processing, one can imagine that the enzyme responsible for the CD40L cleavage belongs to a convertase family of enzymes(13, 20) . The existence of a soluble form of CD40L allowed us to postulate two different pathways of CD40L regulation in the immune response. These soluble forms could represent inactive by-products generated during the down-regulation of CD40L expression. On the other hand, they could represent alternative forms of CD40L displaying biological activities. Previous work has shown that the soluble recombinant form of CD40L is trimeric(15) . We therefore examined whether CD40L released by activated T cells was monomeric or multimeric.

Physical Characterization of the Native Human Soluble CD40L

Soluble forms of CD40L were subjected to sedimentation through a sucrose gradient. The 18-kDa form sedimented as a molecular species with an apparent molecular mass of 56 ± 5 kDa. The 15-kDa form sedimented with an apparent molecular mass of 51 ± 5 kDa. This suggested that the two forms were multimeric and may be trimeric (Fig. 3). The sedimentation technique used does not allow us to make the distinction as to whether soluble forms of CD40L are homo- or heteromultimers. As trimeric forms of recombinant CD40L are active (15) , we examined whether the native soluble forms of CD40L could also participate in the induction of B cell proliferation.


Figure 3: Sucrose gradient sedimentation of the human native soluble CD40L. An aliquot of 100 µl of concentrated, stimulated JF7 supernatant was mixed with 100 µl of biotinylated protein standards and layered onto a 5-20% sucrose gradient in PBS. After centrifugation for 42 h at 40,000 rpm in a SW 41 Ti rotor, fractions were collected, trichloroacetic acid-precipitated, and divided into two pools for analysis with the anti-CD40L mAb to detect CD40L and with the streptavidin horseradish peroxidase-conjugated antibody to reveal the biotinylated molecular mass marker. A, molecular mass of globular protein standards was plotted against fraction number. Sedimentation points of the 18- and 15-kDa native soluble CD40L are indicated. B, fraction from representative gradient was separated by SDS-PAGE, transferred onto nitrocellulose, and blotted with 5 µg/ml human anti-CD40L mAb. Positions of the 18- and 15-kDa CD40L cleavage products are indicated by arrows.



Biological Activity of the Native Human Soluble CD40L

When tested in a B cell proliferation assay, the sucrose gradient fraction 19 (containing soluble CD40L, Fig. 3) was able to induce a 7-fold increase in [^3H]deoxythymidine incorporation in B cells cultured in the presence of IL-4 (Fig. 4). A smaller B cell proliferation was also induced by fraction 3, which does not contain soluble CD40L detectable by Western blot analysis (data not shown). To show that the activity in the sucrose gradient (fraction 19) was indeed mediated by soluble CD40L, soluble CD40-Fc was added as a competitor. The proliferation induced by fraction 19 was partially inhibited, around 30% of inhibition, whereas CD40-Fc had no effects on the proliferation induced by fraction 3 (Fig. 4). These data suggest that fraction 19 contains active soluble CD40L, whereas the activity detected with fraction 3 could correspond to an activity resulting from the presence of cytokines such as IL-1, IL-2, and TNF-alpha produced by T cells(21) .


Figure 4: Biological activity of the native human soluble CD40L. Purified tonsillar B cells were incubated either alone (lane 1), with rIL-4 (lane 2), with rIL-4 and anti-CD40 mAb (lane 3), or with rIL-4 and aliquots of either sucrose gradient fraction 3 or fraction 19 (from lane 4 to 7), and then the [^3H]deoxythymidine incorporation was measured. Results are expressed in counts/min (mean ± S.D.). Lanes 4 and 5, B cells were incubated with 20 µl of the sucrose gradient fraction 19 in the absence or presence of 10 µg/ml CD40-Fc, respectively. Lanes 6 and 7, B cells were incubated with 20 µl of the sucrose gradient fraction 3 in the absence or presence of 10 µg/ml CD40-Fc, respectively.



Whereas it remains to be determined if all the identified soluble forms of CD40L are biologically active, our data suggest that cleavage of CD40L does not simply represent an alternative way to down-regulate the expression of this surface molecule by T cells. It seems unlikely that one of the two forms of the soluble CD40L acts as an antagonist since we have identified them as trimers. Soluble forms produced by intracellular cleavage share activities with the membrane form of CD40L and might therefore be involved in the control of B cell activation by helper T cells. Whereas the 33-kDa membrane form could be detected intracellularly on unstimulated CD4 T cell clone cells by Western blotting assays, surface expression was undetectable by flow cytometry, indicating a post-transcriptional control of surface expression(22) . This would appear to suggest that a preformed CD40L is stored inside unstimulated cells to be readily available in case of an immediate need. The absence of surface expression was paralleled by the CD40L cleavage, suggesting that the release of soluble CD40L by T cells is also tightly regulated.

CD40L is involved in the induction of a large variety of events in the immune system as indicated by the pleiotropic effects of the mutations observed in hyper-IgM syndrome patients(8, 23) . The complex physiology of CD40L might be partially linked to the existence of multiple forms of the protein.

The existence of a membrane-bound and a soluble form of CD40L suggests that this molecule might transmit signals in two different ways. The two different forms could share some activities, but they could also display specific functions. The membrane molecule could be implicated in a cell-cell interaction process, which presents some physical limits of the signal propagation. In contrast the soluble form with its ``cytokine-like activity'' could represent a quick and diffusible way for T cells to transmit the signal.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed.

(^1)
The abbreviations used are: TNF, tumor necrosis factor; IL, interleukin; rIL, recombinant interleukin; mAb, monoclonal antibody; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; PMA, phorbol 12-myristate 13-acetate.


ACKNOWLEDGEMENTS

We thank R. J. Noelle for kindly providing the anti-huCD40L mAb, P. Graber, E. Sebille, and C. Arod for preparing the CD40Fc, E. Magnenat for N-terminal amino acid analysis, C. Hebert for photography, and Drs. K. Hardy and J. Knowles for continued support and helpful discussion.


REFERENCES

  1. Hollenbaugh, D., Grosmaire, L. S., Kullas, C. D., Chalupny, N. J., Braesch-Andersen, S., Noelle, R. J., Stamenkovic, I., Ledbetter, J. A., and Aruffo, A. (1992) EMBO J. 11, 4313-4321 [Abstract]
  2. Armitage, R. J., Fanslow, W. C., Strockbine, L., Sato, T. A., Clifford, K. N., Macduff, B. M., Anderson, D. M., Gimpel, S. D., David-Smith, T., Maliszewski, C. R., Clark, E. A., Smith, C. A., Grabstein, K. H., Cosman, D., and Spriggs, M. K. (1992) Nature 357, 80-82 [CrossRef][Medline] [Order article via Infotrieve]
  3. Noelle, R. J., Roy, M., Shepherd, D. M., Stamenkovic, I., Ledbetter, J. A., and Aruffo, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6550-6554 [Abstract]
  4. Gauchat, J.-F., Henchoz, S., Mazzei, G., Aubry, J.-P., Brunner, T., Blasey, H., Life, P., Talabot, D., Flores-Romo, L., Thompson, J., Kishi, K., Butterfield, J., Dahinden, C., and Bonnefoy, J.-Y. (1993) Nature 365, 340-343 [CrossRef][Medline] [Order article via Infotrieve]
  5. Gauchat, J.-F., Henchoz, S., Fattah, D., Mazzei, G., Aubry, J.-P., Jomotte, T., Dash, L., Page, K., Solari, R., Aldebert D., Capron, M., Dahinden, C., and Bonnefoy, J.-Y. (1995) Eur. J. Immunol. 25, 863-865 [Medline] [Order article via Infotrieve]
  6. Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T., and Kikutani, H. (1994) Immunity 1, 167-178 [Medline] [Order article via Infotrieve]
  7. Renshaw, B. R., Fanslow, W. C., Armitage, R. J., Campbell, K. A., Ligitt, B., Davison, B. L., and Maliszewski, C. R. (1994) J. Exp. Med. 180, 1889-1900 [Abstract]
  8. Aruffo, A., Farrington, M. Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L., Stenkamp, R., Neubauer, M., Roberts, R., Noelle, R., Ledbetter, J., Francke, U., and Ochs, H. D. (1993) Cell 72, 291-300 [Medline] [Order article via Infotrieve]
  9. Korthäuer, U., Graf, D., Mages, H. W., Brières, F., Padayachee, M., Malcolm, S., Ugazio, A. G., Notarangelo, L. D., Levinski, R. J., and Kroczek, R. A. (1993) Nature 361, 539-541 [CrossRef][Medline] [Order article via Infotrieve]
  10. DiSanto, J.-P., Bonnefoy, J.-Y., Gauchat, J.-F., Fischer, A., and de Saint Basile, G. (1993) Nature 361, 541-543 [CrossRef][Medline] [Order article via Infotrieve]
  11. Cutler Allen, R., Armitage, R. J., Conley, M. E., Rosenblatt, H., Jenkins, N. A., Copeland, N. G., Bedell, M. A., Edelhoff, S., Disteche, C. M., Simoneaux, D. K., Fanslow, W. C., Belmont, J., and Spriggs, M. K. (1993) Science 253, 990-993
  12. Facchetti, F., Appiani, C., Salvi, L., Levy, J., and Notarangelo, L. D. (1995) J. Immunol. 154, 6624-6633 [Abstract/Free Full Text]
  13. Kriegler, M., Preez, C., Defay, K., Albert, I., and Lu, S. D. (1988) Cell 53, 45-53 [Medline] [Order article via Infotrieve]
  14. Tanaka, M., Suda, T., Taakahashi, T., and Nagata, S. (1995) EMBO J. 14, 1129-1135 [Abstract]
  15. Mazzei, G. J., Edgerton, M. D., Losberger, C., Lecoanet-Henchoz, S., Graber, P., Durandy, A., Gauchat, J.-F., Bernard, A., Allet, B., and Bonnefoy, J.-Y. (1995) J. Biol. Chem. 270, 7025-7028 [Abstract/Free Full Text]
  16. Graf, D., Müller, S., Korthäuer, U., van Kooten, C., Weise, C., and Kroczek, R. A. (1995) Eur. J. Immunol. 25, 1749-1754 [Medline] [Order article via Infotrieve]
  17. Martin, T. F. J. (1989) Methods Enzymol. 168, 225-233 [Medline] [Order article via Infotrieve]
  18. Burnette, W. N. (1981) Anal. Biochem. 112, 195 [Medline] [Order article via Infotrieve]
  19. Gauchat, J. F., Aubry, J. P., Mazzei, G., Life, P., Jomotte, T., Elson, G., and Bonnefoy, J. Y. (1993) FEBS Lett. 315, 259-266 [CrossRef][Medline] [Order article via Infotrieve]
  20. Cerretti, D. P., Kozlosky, C. J., Mosley, B., Nelson, N., van Ness, K., Greenstreet, T. A., March, C. J., Kroheim, S. R., Druk, T., Cannizzaro, L. A., Huebner, K., and Black, R. A. (1992) Science 256, 97-100 [Medline] [Order article via Infotrieve]
  21. Tucci, A., James, H., Chicheportiche, R., Bonnefoy, J. Y., Dayer, J. M., and Zubler, R. H. (1992) J. Immunol. 148, 2778-2784 [Abstract/Free Full Text]
  22. Casamayor-Palleja, M., and MacLennan, K. M. (1995) J. Exp. Med. 181, 1293-1301 [Abstract]
  23. Notarangelo, L. D., Mantuano, E., Bione, S., Gimbo, E., Giliani, S., Caraffini, A.,Purtilo, D., Farr, C. C., Ugazio, A. G., and Toniolo, D. (1993) Immunodeficiency 4, 225-229 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.